These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25013959)

  • 1. Surfactant-based drug delivery systems for treating drug-resistant lung cancer.
    Kaur P; Garg T; Rath G; Murthy RS; Goyal AK
    Drug Deliv; 2016; 23(3):727-38. PubMed ID: 25013959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
    Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
    Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
    Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
    Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells.
    Gao L; Liu G; Ma J; Wang X; Wang F; Wang H; Sun J
    Colloids Surf B Biointerfaces; 2014 May; 117():122-7. PubMed ID: 24632038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanoemulsions for anti-cancer drug therapy.
    Souto EB; Nayak AP; Murthy RS
    Pharmazie; 2011 Jul; 66(7):473-8. PubMed ID: 21812320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy.
    Huang P; Wang D; Su Y; Huang W; Zhou Y; Cui D; Zhu X; Yan D
    J Am Chem Soc; 2014 Aug; 136(33):11748-56. PubMed ID: 25078892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine for Treatment of Lung Cancer.
    Hussain S
    Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
    Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
    J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment.
    Iangcharoen P; Punfa W; Yodkeeree S; Kasinrerk W; Ampasavate C; Anuchapreeda S; Limtrakul P
    Arch Pharm Res; 2011 Oct; 34(10):1679-89. PubMed ID: 22076768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
    Malam Y; Loizidou M; Seifalian AM
    Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line.
    Huffman KE; Corey DR
    Biochemistry; 2005 Feb; 44(7):2253-61. PubMed ID: 15709737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.
    Ai Y; Zhu B; Ren C; Kang F; Li J; Huang Z; Lai Y; Peng S; Ding K; Tian J; Zhang Y
    J Med Chem; 2016 Mar; 59(5):1747-60. PubMed ID: 26891099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
    Misra R; Das M; Sahoo BS; Sahoo SK
    Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nanoparticulate systems for lung cancer therapy: an updated review.
    Madni A; Batool A; Noreen S; Maqbool I; Rehman F; Kashif PM; Tahir N; Raza A
    J Drug Target; 2017 Jul; 25(6):499-512. PubMed ID: 28151021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactants: their critical role in enhancing drug delivery to the lungs.
    Morales JO; Peters JI; Williams RO
    Ther Deliv; 2011 May; 2(5):623-41. PubMed ID: 22833979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-L-asparagine nanocapsules as anticancer drug delivery vehicles.
    Rivera-Rodríguez GR; Alonso MJ; Torres D
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):481-7. PubMed ID: 23954509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.